Huiya Wu

Featured in: Favicon

jdsupra.com Favicon

mondaq.com Favicon

iam-media.com Favicon

lexblog.com

Articles

Are Reference Product Sponsors Asserting More Patents in BPCIA Litigation? | JD Supra

Jan 2, 2025 | jdsupra.com | Huiya Wu

On October 24, 2014, Amgen initiated the first litigation under the Biologics Price Competition and Innovation Act (“BPCIA”), asserting infringement of two patents. Over the last two calendar years, Amgen, Biogen, Genentech, and Regeneron have all filed BPCIA complaints (sometimes several) asserting 20 or more patents.
Life Sciences M&A Trends For 2023 And 2024 (Through End Of Q3) In Greater China

Nov 13, 2024 | mondaq.com | David Chen |Huiya Wu |Kristopher Brown |Krystal J. Lin

Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China's life sciences sector. See the first post in the series here. While the overall Chinese M&A market fluctuated from 2021 to 2023 due to the pandemic and other factors, the life sciences pharmaceutical and biotech market remained relatively stable. Though the number of deals dipped in 2022, in 2023, it quickly recovered to 2021 levels.
Amgen And Sandoz Settle Denosumab BPCIA Litigation

May 20, 2024 | mondaq.com | Huiya Wu

we previously reported, in May 2023, Amgen filed a BPCIA complaint in the District of New Jersey alleging infringement based on Sandoz's denosumab biosimilars of Amgen's PROLIA and XGEVA ("the Sandoz Denosumab Litigation"). The FDA subsequently, in March 2024, approved Sandoz's denosumab biosimilars, WYOST (denosumab-bbdz) and JUBBONTI (denosumab-bbdz), as interchangeable with Amgen's XGEVA and PROLIA products.
Amgen and Sandoz Settle Denosumab BPCIA Litigation | JD Supra

May 16, 2024 | jdsupra.com | Huiya Wu

As we previously reported, in May 2023, Amgen filed a BPCIA complaint in the District of New Jersey alleging infringement based on Sandoz’s denosumab biosimilars of Amgen’s PROLIA and XGEVA (“the Sandoz Denosumab Litigation”). The FDA subsequently, in March 2024, approved Sandoz’s denosumab biosimilars, WYOST (denosumab-bbdz) and JUBBONTI (denosumab-bbdz), as interchangeable with Amgen’s XGEVA and PROLIA products.
Amgen and Sandoz Settle Denosumab BPCIA Litigation

May 15, 2024 | bigmoleculewatch.com | Huiya Wu

As we previously reported, in May 2023, Amgen filed a BPCIA complaint in the District of New Jersey alleging infringement based on Sandoz’s denosumab biosimilars of Amgen’s PROLIA and XGEVA (“the Sandoz Denosumab Litigation”). The FDA subsequently, in March 2024, approved Sandoz’s denosumab biosimilars, WYOST (denosumab-bbdz) and JUBBONTI (denosumab-bbdz), as interchangeable with Amgen’s XGEVA and PROLIA products.
Major Life Sciences Licensing Deal Trends In China In 2023

Mar 19, 2024 | mondaq.com | David Chen |Huiya Wu |Yoko Bian

An in-depth look at trends involving licensing deals in a year that saw a significant increase in out-licensing and particularly in-licensing activity in China. This is the first of two articles focused on 2023 life sciences deals in China. The second article, which is coming soon, looks at trends in M&A. In 2023, there were 240 reported life sciences licensing deals in China, an increase of almost 50% compared to 2021.
Major Life Sciences Licensing Deal Trends in China in 2023

Mar 14, 2024 | lexblog.com | Huiya Wu |Yoko Bian |Summer Lawson |David Chen

This is the first of two articles focused on 2023 life sciences deals in China. The second article, which is coming soon, looks at trends in M&A. In 2023, there were 240 reported life sciences licensing deals in China, an increase of almost 50% compared to 2021. That includes 70 out-license deals involving Chinese companies licensing drugs and technologies to foreign companies, with a disclosed aggregate deal value surpassing US$35 billion.
Women’s History Month Spotlight: Brigitte Askonas | JD Supra

Mar 10, 2023 | jdsupra.com | Huiya Wu

In honor of Women’s History Month, Big Molecule Watch recognizes Brigitte “Ita” Askonas, widely regarded as the mother of modern immunology. Born one hundred years ago, Dr. Askonas contributed to our understanding of the origin and synthesis of antibodies and the body’s immune response.
Women’s History Month Spotlight: Brigitte Askonas

Mar 9, 2023 | lexblog.com | Huiya Wu

In honor of Women’s History Month, Big Molecule Watch recognizes Brigitte “Ita” Askonas, widely regarded as the mother of modern immunology. Born one hundred years ago, Dr. Askonas contributed to our understanding of the origin and synthesis of antibodies and the body’s immune response.
Women’s History Month Spotlight: Brigitte Askonas

Mar 9, 2023 | bigmoleculewatch.com | Huiya Wu

antibodies, B cells, Immunology, lymphocytes, Women's History Month In honor of Women’s History Month, Big Molecule Watch recognizes Brigitte “Ita” Askonas, widely regarded as the mother of modern immunology. Born one hundred years ago, Dr. Askonas contributed to our understanding of the origin and synthesis of antibodies and the body’s immune response.